The benefits of adding metformin to tamoxifen to protect the endometrium—A randomized placebo‐controlled trial

We investigated whether metformin prevents tamoxifen‐induced endometrial changes and insulin resistance (IR) after a diagnosis of breast cancer.

[1]  Yan Zhao,et al.  Metformin is associated with reduced cell proliferation in human endometrial cancer by inbibiting PI3K/AKT/mTOR signaling , 2018, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[2]  L. Keinan-Boker,et al.  Diabetes After Hormone Therapy in Breast Cancer Survivors: A Case-Cohort Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Mitsuhashi,et al.  Antitumor effects of metformin via indirect inhibition of protein phosphatase 2A in patients with endometrial cancer , 2018, PloS one.

[4]  Chuanying Sun,et al.  Association of abnormal glucose metabolism and insulin resistance in patients with atypical and typical endometrial cancer , 2017, Oncology letters.

[5]  L. A. Simeoni,et al.  Effects of metformin on endometrial cancer: Systematic review and meta-analysis. , 2017, Gynecologic oncology.

[6]  T. Wadden,et al.  Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): study design , 2017, npj Breast Cancer.

[7]  F. Mauvais-Jarvis,et al.  The effect of selective estrogen receptor modulators on type 2 diabetes onset in women: Basic and clinical insights. , 2017, Journal of diabetes and its complications.

[8]  S. Mansuria,et al.  Threshold for endometrial sampling among postmenopausal patients without vaginal bleeding , 2016, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[9]  Balwinder Kaur,et al.  Endometrial evaluation by ultrasonography, hysteroscopy and histopathology in cases of breast carcinoma on Tamoxifen therapy , 2015, Journal of mid-life health.

[10]  S. Davis,et al.  Metformin for overweight women at midlife: a double-blind, randomized, controlled trial , 2015, Climacteric : the journal of the International Menopause Society.

[11]  S. Davis,et al.  Obesity is associated with a poorer prognosis in women with hormone receptor positive breast cancer. , 2014, Maturitas.

[12]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[13]  Chunxiao Zhou,et al.  Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway. , 2012, Gynecologic oncology.

[14]  N. Harbeck,et al.  Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: results of a prospective gynecological ultrasound substudy. , 2010, Gynecologic oncology.

[15]  Kwok-Kin Wong,et al.  Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy , 2010, Disease Models & Mechanisms.

[16]  Chunxiao Zhou,et al.  Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. , 2010, Gynecologic oncology.

[17]  G. Take,et al.  Effects of metformin on mammalian target of rapamycin in a mouse model of endometrial hyperplasia. , 2009, European journal of obstetrics, gynecology, and reproductive biology.

[18]  M. Beckmann,et al.  Early aberrant insulin‐like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen , 2008, International journal of cancer.

[19]  B. Bonanni,et al.  Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. , 2008, Cancer research.

[20]  Jin-fang Lin,et al.  Reverse of Progestin-Resistant Atypical Endometrial Hyperplasia by Metformin and Oral Contraceptives , 2008, Obstetrics and gynecology.

[21]  J. Johansson,et al.  Accepting and adjusting: older women's experiences of living with urinary incontinence. , 2008, Urologic nursing.

[22]  L. Vatten,et al.  Body mass, diabetes and smoking, and endometrial cancer risk: a follow-up study , 2008, British Journal of Cancer.

[23]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[24]  A. Bianco,et al.  The ATAC ('Arimidex', Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. , 2006, Human reproduction.

[25]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[26]  H. Nagai,et al.  Plasma Leptin Concentration in Tamoxifen-Treated Ovariectomized Rats , 2005, Gynecologic and Obstetric Investigation.

[27]  O. Develioǧlu,et al.  The endometrium in asymptomatic breast cancer patients on tamoxifen: value of transvaginal ultrasonography with saline infusion and Doppler flow. , 2004, Gynecologic oncology.

[28]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[29]  J. Barkin,et al.  Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach , 2003, American Journal of Gastroenterology.

[30]  K. Kalli,et al.  Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent , 2003, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[31]  P. Causer,et al.  Transvaginal US and hysterosonography in postmenopausal women with breast cancer receiving tamoxifen: correlation with hysteroscopy and pathologic study. , 2003, Radiographics : a review publication of the Radiological Society of North America, Inc.

[32]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[33]  T. Saibara,et al.  Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. , 2000, Oncology reports.

[34]  T. Reimer,et al.  Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  H. Hollema,et al.  Risk and prognosis of endometrial cancer after tamoxifen for breast cancer , 2000, The Lancet.

[36]  F. Penault-Llorca,et al.  Endometrial histopathology in 700 patients treated with tamoxifen for breast cancer. , 2000, Gynecologic oncology.

[37]  P. Stolley,et al.  Endometrial cancer and estrogen use. Report of a large case-control study. , 1979, The New England journal of medicine.